
Vascular disease isn’t going away. Real people continue to fight the progression and complications that result from PAD. We’ve won many battles but the war goes on and we don’t take our responsibility to create change lightly. As our company ages, many of our ideas have become realities yet we still lie awake at night devising plans to do more. We know many are counting on us to do more. We continue to be an ordinary group of individuals trying to achieve the extraordinary. For this opportunity we remain extremely blessed.
Location: United States, California, Redwood City
Employees: 51-200
Phone: +1 650-363-2400
Total raised: $146.7M
Founded date: 2007
Investors 2
Date | Name | Website |
- | Emergent M... | emvllp.com |
- | CRG | crglp.com |
Funding Rounds 6
Date | Series | Amount | Investors |
25.08.2020 | - | $5.2M | - |
06.08.2020 | - | $6M | - |
23.09.2015 | - | $55M | CRG |
10.07.2012 | Series D | $33M | - |
09.01.2012 | Series C | $22.5M | - |
11.01.2011 | Series B | $25M | - |
Mentions in press and media 21
Date | Title | Description |
28.01.2025 | Peytant Solutions hires chief medical and commercial officers | Peytant Solutions today announced it hired Dr. Craig Walker as chief medical officer after naming JD Simpson as chief commercial officer last week. The Plymouth, Minnesota-based stent maker won FDA de novo marketing authorization for its AM... |
27.01.2025 | Asia's Venture Capital Landscape: A Tale of Peaks and Valleys | The venture capital scene in Asia is a rollercoaster ride. Last year, it hit a low that echoed the past. The funding market plummeted to $65.8 billion, matching the dismal figures of 2014. It’s a stark reminder that what goes up can come cr... |
22.01.2025 | Peytant Solutions Welcomes JD Simpson as Chief Commercial Officer | JD Simpson, Chief Commercial Officer, Peytant Solutions Peytant Solutions Inc., a medical technology company pioneering the use of amnion-based covered scaffolds for the treatment of luminal disease, announced the appointment of JD Simpson ... |
26.08.2024 | Zylox-Tonbridge Reports Strong Interim Financial Results for 2024, Achieving Significant Growth and Profitability | HANGZHOU, China, Aug. 26, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK), a leading player in China's peripheral and neurovascular intervention markets, today announced its interim financial results for 2024. Th... |
22.03.2024 | Zylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability | HANGZHOU, China, March 22, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial res... |
07.03.2024 | Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions | HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partners... |
08.08.2022 | Avinger, Inc. Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-the-Market Under Nasdaq Rules | REDWOOD CITY, CA / ACCESSWIRE / August 8, 2022 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems... |
21.06.2022 | Avinger Expands International Presence with First Commercial Shipment to Chile | REDWOOD CITY, CA / ACCESSWIRE / June 21, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral ... |
06.06.2022 | Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference | REDWOOD CITY, CA / ACCESSWIRE / June 6, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral A... |
19.01.2022 | AVINGER : ANNOUNCES CLOSING OF $7.6 MILLION REGISTERED DIRECT OFFERING - Form 8-K | AVINGER, INC. ANNOUNCES CLOSING OF $7.6 MILLION REGISTERED DIRECT OFFERING REDWOOD CITY, CA / January 14, 2022 / Avinger, Inc. (NASDAQ: AVGR) (the "Company"), a commercial-stage medical device company marketing the first and only ... |
Show more